Monoclonal antibody therapy that targets phospholipid-binding protein delays lupus activity in MRL/lpr mice.
Animals
Annexin A1
/ antagonists & inhibitors
Antibodies, Monoclonal
/ pharmacology
Autoantibodies
/ immunology
Biomarkers
Cytokines
/ metabolism
Disease Models, Animal
Disease Progression
Humans
Immunoglobulin G
/ immunology
Immunologic Factors
/ pharmacology
Lupus Erythematosus, Systemic
/ drug therapy
Mice
Mice, Inbred MRL lpr
Proteinuria
/ etiology
Spleen
/ immunology
T-Lymphocytes
/ immunology
Treatment Outcome
MRL/lpr mice
anti-annexin A1 antibody
antibody therapy
autoreactive T and B cells
systemic lupus
Journal
Scandinavian journal of immunology
ISSN: 1365-3083
Titre abrégé: Scand J Immunol
Pays: England
ID NLM: 0323767
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
06
03
2020
revised:
14
05
2020
accepted:
03
06
2020
pubmed:
14
6
2020
medline:
8
9
2020
entrez:
14
6
2020
Statut:
ppublish
Résumé
Systemic lupus erythematosus is an autoimmune syndrome characterized by the development of autoantibodies to a wide range of antigens. Together with B cells, respective self-reactive T cells have an important contribution in disease progression as being responsible for inflammatory cytokines secretion, B cell activation and promoting amplification of the autoimmune response. Annexin A1 is expressed by many cell types and binds to phospholipids in a Ca
Substances chimiques
ANXA1 protein, human
0
Annexin A1
0
Antibodies, Monoclonal
0
Autoantibodies
0
Biomarkers
0
Cytokines
0
Immunoglobulin G
0
Immunologic Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12915Subventions
Organisme : Bulgarian National Science Fund
ID : DDVU 02/34
Organisme : Bilateral grant between Bulgarian Academy of Sciences and Hungarian Academy of Sciences
ID : SNK-73/2013
Informations de copyright
© 2020 The Scandinavian Foundation for Immunology.
Références
Dörner T, Giesecke C, Lipsky PE. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther. 2011;13(5):243.
Wilkinson MGL, Rosser EC. B cells as a therapeutic target in paediatric rheumatic disease. Front Immunol. 2019;10:214.
Tai Y, Wang Q, Korner H, Zhang L, Wei W. Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases. Front Pharmacol. 2018;9:642.
Crispín J, Kyttaris VC, Terhors C, et al. T cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6:317-325.
Merrill JT, Burgos-Vargas R, Chalmers WR, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:3077-3087.
Zhang Q, Vignali D. Co-stimulatory and co-inhibitory pathways in autoimmunity. Immunity. 2016;44(5):1034-1051.
Sheikh MH, Solito E. Annexin A1: uncovering the many talents of an old protein. Int J Mol Sci. 2018;19:1045.
Perretti M, D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol. 2009;9:62-70.
Yang YH, Morand E, Leech M. Annexin A1: potential for glucocorticoid sparing in RA. Nat Rev Rheumatol. 2013;9:595-603.
Bruschi M, Petretto A, Vaglio A, Santucci L, Candiano G, Ghiggeri GM. Annexin A1 and autoimmunity: from basic science to clinical applications. Int J Mol Sci. 2018;19:1-13.
Yang YH, Song W, Deane JA, et al. Deficiency of annexin A1 in CD4+ T cells exacerbates T cell-dependent inflammation. J Immunol. 2013;190:997-1007.
D'Acquisto F, Merghani A, Lecona E, et al. Annexin-1 modulates T-cell activation and differentiation. Blood. 2007;109:1095-1102.
Paschalidis N, Huggins A, Rowbotham NJ, et al. Role of endogenous annexin-A1 in the regulation of thymocyte positive and negative selection. Cell Cycle. 2010;9:784-793.
Paschalidis N, Iqbal AJ, Maione F, et al. Modulation of experimental autoimmune encephalomyelitis by endogenous annexin A1. J Neuroinflamm. 2009;6:33.
Kretz C, Norpo M, Abeler-Dorner L, et al. Anti-annexin 1 antibodies: a new diagnostic marker in the serum of patients with discoid lupus erythematosus. Exp Dermatol. 2010;19:919-930.
Spurr L, Nadkarni S, Pederzoli-Ribeil M, et al. Comparative analysis of Annexin A1-formyl peptide receptor 2/ALX expression in human leukocyte subsets. Int Immunopharmacol. 2011;11:55-66.
Bonanni A, Vaglio A, Bruschi M, et al. Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference. Autoimmun Rev. 2015;14:692-702.
Bruschi M, Sinico R, Moroni G, et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo: alpha-enolase and annexin AI. J Am Soc Nephrol. 2014;25:2483-2498.
Bruschi M, Galetti M, Sinico RA, et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): planted antigens. J Am Soc Nephrol. 2015;26:1905-1924.
Rottman JB, Willis CR. Mouse models of systemic lupus erythematosus reveal a complex pathogenesis. Vet Pathol. 2010;47(4):664-676.
Mihaylova N, Bradyanova S, Chipinski P, et al. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus. Autoimmunity. 2017;50(4):257-268.
Mihaylova N, Chipinski P, Bradyanova S, et al. Suppression of autoreactive T and B lymphocytes by anti-Annexin A1 antibody in humanized NSG murine model of systemic lupus erythematosus. Clin Exp Immonol. 2019;199:278-293.
Tchorbanov AI, Voynova EN, Mihaylova NM, et al. Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice. Eur J Immunol. 2007;37:3587-3596.
Richard M, Gilkeson G. Mouse models of lupus: what they tell us and what they don't. Lupus Sci Med. 2018;5(1):e000199.
Ahuja A, Shupe J, Dunn R, et al. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol. 2007;179:3351-3361.
Kansal R, Richardson N, Neeli I, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019;11(482):eaav1648.
Hoyer BF, Moser K, Hauser AE, et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J. Exp. Med. 2004;199:1577-1584.
Renshaw D, Montero-Melendez T, Dalli J, et al. Downstream gene activation of the receptor ALX by the agonist Annexin A1. PLoS One. 2010;5:e12771.
Pham TH, Okada M, Matloubian M, et al. S1P1 receptor signaling overrides retention mediated by Gαi-coupled receptors to promote T cell egress. Immunity. 2008;28:122-133.
Moudgil K, Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res. 2011;31(10):695-703.
He C, Feng P, Su H, Gu A, Yan Z, Zhu X. Disrupted Th1/Th2 balance in patients with rheumatoid arthritis (RA). Int J Clin Exp Pathol. 2017;10(2):1233-1242.
Jackson S, Jacobs H, Arkatkar T, et al. B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. JEM. 2016;213(5):733.
Pollard K, Cauvi D, Toomey C, Morris K, Kono D. Interferon-γ and systemic autoimmunity. Discov Med. 2013;16(87):123-131.
Bobe P, Bonardelle D, Benihoud K, et al. Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/ lpr mice. Blood. 2006;108:3967-3975.
Juvet SC, Zhang L. Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directions. J Mol Cell Biol. 2012;4(1):48-58.
Foster M. T cells and B cells in lupus nephritis. Semin Nephrol. 2007;27:47-58.
Teichmann LL, Kashgarian M, Weaver CT, Roers A, Müller W, Shlomchik MJ. B cell-derived IL-10 does not regulate spontaneous systemic autoimmunity in MRL.Fas(lpr) mice. J Immunol. 2012;188(2):678-685.
Rojas M, Rodríguez Y, Leon KJ, et al. Cytokines and inflammatory mediators in systemic lupus erythematosus. EMJ Rheumatol. 2018;5(1):83-92.